Mela Sciences Shares Surge After FDA Approves Cancer Test

Mela Sciences Inc. (MELA), the maker of the MelaFind melanoma-detection device, gained 19 percent after receiving Food and Drug Administration approval to sell the product in the U.S.

Mela rose to $6.42 at 8:10 a.m. The Irvington, New York- based company said in a statement today that it plans to first introduce the test in the northeastern U.S. in 2012.

To contact the reporter on this story: Bruce Rule in New York at brule1@bloomberg.net

To contact the editor responsible for this story: Reg Gale at Rgale5@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.